Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF)

被引:72
作者
Czubak, Anna [1 ]
Nowakowska, Elzbieta [1 ]
Kus, Krzysztof [1 ]
Burda, Kinga [1 ]
Metelska, Jana [1 ]
Baer-Dubowska, Wanda [2 ]
Cichocki, Michal [2 ]
机构
[1] Univ Med Sci, Dept Pharmacoecon & Social Pharm, PL-60529 Poznan, Poland
[2] Univ Med Sci, Dept Pharmaceut Biochem, PL-60781 Poznan, Poland
关键词
brain-derived neurotrophic factor; venlafaxine; olanzapine; nicotine; rat brain; FACTOR MESSENGER-RNA; FACTOR GENE-EXPRESSION; NERVE GROWTH-FACTOR; PREFRONTAL CORTEX; RAT HIPPOCAMPUS; ANTIDEPRESSANT; RECEPTOR; INCREASES; MODELS; TRKB;
D O I
10.1016/S1734-1140(09)70163-X
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Brain-derived neurotrophic factor (BDNF) is a key neurotrophic factor in the brain. It plays an important role in the etiopathogenesis and pharmacotherapy of mental disorders, such as depression or schizophrenia. In recent years, studies have shown that Cognitive processes, which arc impaired in the Course of mental disorders, significantly change BDNF levels in the brain. Administered to rats at a dose of 20 mg/kg (b.d. for 5 weeks), venlafaxine (VEN) increases BDNF levels in the hippocampus and cortex, compared to controls. Administered at a dose of 0.5 mg/kg (b.d. for 5 weeks), olanzapine (OLA) significantly increases BDNF levels in both the cortex and the hippocampus. Similarly, nicotine (NIC) administered at a dose of 0.2 mg/kg (b.d. for 5 weeks) increases BDNF concentrations in both the hippocampus and the cortex. Combined administration of NIC with VEN or OLA does not increase BDNF levels in the hippocampus or the cortex. Based on our study, it can be claimed that BDNF mediates behavioral responses only to drugs used individually and participates in the antidepressant and procognitive effects of the study compounds. BDNF also initiates plastic changes and modulation of synaptic activity in rat brains.
引用
收藏
页码:1017 / 1023
页数:7
相关论文
共 64 条
[1]
Serotonin model of schizophrenia: emerging role of glutamate mechanisms [J].
Aghajanian, GK ;
Marek, GJ .
BRAIN RESEARCH REVIEWS, 2000, 31 (2-3) :302-312
[2]
Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders [J].
Aloe, L ;
Iannitelli, A ;
Angelucci, F ;
Bersani, G ;
Fiore, M .
BEHAVIOURAL PHARMACOLOGY, 2000, 11 (3-4) :235-242
[3]
Neurotrophin trafficking by anterograde transport [J].
Altar, CA ;
DiStefano, PS .
TRENDS IN NEUROSCIENCES, 1998, 21 (10) :433-437
[4]
Neurotrophic factors and CNS disorders:: findings in rodent models of depression and schizophrenia [J].
Angelucci, F ;
Mathé, AA ;
Aloe, L .
NGF AND RELATED MOLECULES IN HEALTH AND DISEASE, 2004, 146 :151-165
[5]
Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs [J].
Bai, O ;
Chlan-Fourney, J ;
Bowen, R ;
Keegan, D ;
Li, XM .
JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 71 (01) :127-131
[6]
BERNINGER B, 1995, DEVELOPMENT, V121, P2327
[7]
Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein [J].
Calabrese, Francesca ;
Molteni, Raffaella ;
Maj, Paola F. ;
Cattaneo, Annamaria ;
Gennarelli, Massimo ;
Racagni, Giorgio ;
Riva, Marco A. .
NEUROPSYCHOPHARMACOLOGY, 2007, 32 (11) :2351-2359
[8]
Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication [J].
Chen, B ;
Dowlatshahi, D ;
MacQueen, GM ;
Wang, JF ;
Young, LT .
BIOLOGICAL PSYCHIATRY, 2001, 50 (04) :260-265
[9]
Bi-phasic change in BDNF gene expression following antidepressant drug treatment [J].
Coppell, AL ;
Pei, Q ;
Zetterström, TSC .
NEUROPHARMACOLOGY, 2003, 44 (07) :903-910
[10]
The effect of nicotine and mecamylamine on spatial memory in rats [J].
Czubak, A. ;
Nowakowska, E. ;
Kus, K. ;
Matschay, A. ;
Kokot, Z. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 :S253-S254